CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SIGA Technologies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SIGA Technologies Inc
31 East 62Nd Street
Phone: (212) 672-9100p:212 672-9100 NEW YORK, NY  10065  United States Ticker: SIGASIGA
Emerged from Bankruptcy on 4/12/2016
Business Summary
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director DiemNguyen 53 1/27/2024 1/27/2024
Chief Financial Officer, Executive Vice President, Corporate Secretary Daniel J.Luckshire 54 2/10/2011 2/10/2011
Executive Vice President, Chief Scientific Officer Dennis E.Hruby 73 12/1/2020 4/1/1997
6 additional Officers and Directors records available in full report.

Business Names
Business Name
SIGA
Siga Acquisition Corp. Delaware
Siga Technologies, Inc. United Kingdom
SIGAQ

General Information
Number of Employees: 46 (As of 2/14/2025)
Outstanding Shares: 71,441,083 (As of 4/17/2025)
Shareholders: 34
Stock Exchange: NASD
Federal Tax Id: 133864870
Fax Number: (212) 697-3130
Email Address: tkonatich@siga.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 13, 2025